---
title: "MacroGenics, Inc. (MGNX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MGNX.US.md"
symbol: "MGNX.US"
name: "MacroGenics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T08:14:02.002Z"
locales:
  - [en](https://longbridge.com/en/quote/MGNX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MGNX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MGNX.US.md)
---

# MacroGenics, Inc. (MGNX.US)

## Company Overview

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.macrogenics.com](https://www.macrogenics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.62)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 254 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.97% |  |
| Net Profit YoY | -26.06% |  |
| P/B Ratio | 13.55 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 287291507.36 |  |
| Revenue | 157083000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -140.27% | E |
| Profit Margin | -44.79% | E |
| Gross Margin | 54.13% | B |
| Revenue YoY | 1.97% | C |
| Net Profit YoY | -26.06% | D |
| Total Assets YoY | -2.98% | D |
| Net Assets YoY | -73.21% | E |
| Cash Flow Margin | 99.44% | C |
| OCF YoY | 1.97% | C |
| Turnover | 0.71 | B |
| Gearing Ratio | 90.27% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - MacroGenics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-26.06%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "13.55",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "287291507.36",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "157083000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-140.27%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-44.79%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "54.13%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "1.97%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-26.06%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.98%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-73.21%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "99.44%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "1.97%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.71",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "90.27%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.08 | 356/386 | - | - | - |
| PB | 13.55 | 403/386 | 2.71 | 1.70 | 1.28 |
| PS (TTM) | 1.83 | 48/386 | 1.06 | 0.70 | 0.62 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 29% |
| Overweight | 1 | 14% |
| Hold | 4 | 57% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.52 |
| Highest Target | 9.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MGNX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MGNX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MGNX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MGNX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**